| Urgent Care Center, Llc | |
|
1701 Main Ave Sw Suite A Cullman AL 35055-5250 | |
| (256) 737-0880 | |
| Not Available |
| Full Name | Urgent Care Center, Llc |
|---|---|
| Speciality | Internal Medicine |
| Location | 1701 Main Ave Sw, Cullman, Alabama |
| Authorized Official Name and Position | Thomas Oliver (DIRECTOR/OWNER) |
| Authorized Official Contact | 2567370880 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Urgent Care Center, Llc Po Box 870 Cullman AL 35056-0870 Ph: () - | Urgent Care Center, Llc 1701 Main Ave Sw Suite A Cullman AL 35055-5250 Ph: (256) 737-0880 |
| NPI Number | 1245274000 |
|---|---|
| Provider Enumeration Date | 06/15/2006 |
| Last Update Date | 12/20/2022 |
| Medicare PECOS PAC ID | 5294622379 |
|---|---|
| Medicare Enrollment ID | O20040303000186 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy.
The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.
For those who suffer from stomach ulcers, the daily routine of breakfast, lunch and dinner can be painful. A common cause of these ulcers, as well as other gastric malignancies, is a bacterium called Helicobacter pylori .
Guidant Corporation has received Conformité Européenne (CE) Mark approval to launch its CONTAK RENEWAL 4 cardiac resynchronization therapy defibrillators for use outside the United States.
Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245274000 | NPI | - | NPPES |
| CK5467 | Other | AL | RAILROAD MEDICARE |
| 529913650 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Primary |
| Provider Name | Thomas B Oliver |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1194761825 PECOS PAC ID: 2567359656 Enrollment ID: I20040303000264 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy.
The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.
For those who suffer from stomach ulcers, the daily routine of breakfast, lunch and dinner can be painful. A common cause of these ulcers, as well as other gastric malignancies, is a bacterium called Helicobacter pylori .
Guidant Corporation has received Conformité Européenne (CE) Mark approval to launch its CONTAK RENEWAL 4 cardiac resynchronization therapy defibrillators for use outside the United States.
Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.
› Verified 7 days ago
| Provider Name | Gary E Holland |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1962457077 PECOS PAC ID: 8325935406 Enrollment ID: I20060209000033 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy.
The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.
For those who suffer from stomach ulcers, the daily routine of breakfast, lunch and dinner can be painful. A common cause of these ulcers, as well as other gastric malignancies, is a bacterium called Helicobacter pylori .
Guidant Corporation has received Conformité Européenne (CE) Mark approval to launch its CONTAK RENEWAL 4 cardiac resynchronization therapy defibrillators for use outside the United States.
Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.
› Verified 7 days ago
| Provider Name | Archie D Hooper |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1780614867 PECOS PAC ID: 3678578945 Enrollment ID: I20060919000480 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy.
The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.
For those who suffer from stomach ulcers, the daily routine of breakfast, lunch and dinner can be painful. A common cause of these ulcers, as well as other gastric malignancies, is a bacterium called Helicobacter pylori .
Guidant Corporation has received Conformité Européenne (CE) Mark approval to launch its CONTAK RENEWAL 4 cardiac resynchronization therapy defibrillators for use outside the United States.
Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.
› Verified 7 days ago
| Provider Name | Jeremy V Stidham |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1285821397 PECOS PAC ID: 1759465560 Enrollment ID: I20080303000441 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy.
The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.
For those who suffer from stomach ulcers, the daily routine of breakfast, lunch and dinner can be painful. A common cause of these ulcers, as well as other gastric malignancies, is a bacterium called Helicobacter pylori .
Guidant Corporation has received Conformité Européenne (CE) Mark approval to launch its CONTAK RENEWAL 4 cardiac resynchronization therapy defibrillators for use outside the United States.
Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.
› Verified 7 days ago
| Provider Name | Richard P Dodd |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1275755688 PECOS PAC ID: 2365520913 Enrollment ID: I20080422000655 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy.
The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.
For those who suffer from stomach ulcers, the daily routine of breakfast, lunch and dinner can be painful. A common cause of these ulcers, as well as other gastric malignancies, is a bacterium called Helicobacter pylori .
Guidant Corporation has received Conformité Européenne (CE) Mark approval to launch its CONTAK RENEWAL 4 cardiac resynchronization therapy defibrillators for use outside the United States.
Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.
› Verified 7 days ago
| Provider Name | Adam C Harrison |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1922329267 PECOS PAC ID: 5890930424 Enrollment ID: I20130401000455 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy.
The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.
For those who suffer from stomach ulcers, the daily routine of breakfast, lunch and dinner can be painful. A common cause of these ulcers, as well as other gastric malignancies, is a bacterium called Helicobacter pylori .
Guidant Corporation has received Conformité Européenne (CE) Mark approval to launch its CONTAK RENEWAL 4 cardiac resynchronization therapy defibrillators for use outside the United States.
Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.
› Verified 7 days ago
| Provider Name | Christopher R Bailey |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1750609350 PECOS PAC ID: 2769624097 Enrollment ID: I20130815000354 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy.
The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.
For those who suffer from stomach ulcers, the daily routine of breakfast, lunch and dinner can be painful. A common cause of these ulcers, as well as other gastric malignancies, is a bacterium called Helicobacter pylori .
Guidant Corporation has received Conformité Européenne (CE) Mark approval to launch its CONTAK RENEWAL 4 cardiac resynchronization therapy defibrillators for use outside the United States.
Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.
› Verified 7 days ago
| Provider Name | Justin T Cooke |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1285820936 PECOS PAC ID: 9830223635 Enrollment ID: I20160713000119 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy.
The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.
For those who suffer from stomach ulcers, the daily routine of breakfast, lunch and dinner can be painful. A common cause of these ulcers, as well as other gastric malignancies, is a bacterium called Helicobacter pylori .
Guidant Corporation has received Conformité Européenne (CE) Mark approval to launch its CONTAK RENEWAL 4 cardiac resynchronization therapy defibrillators for use outside the United States.
Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.
› Verified 7 days ago
| Provider Name | Erin D Britt |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1790282655 PECOS PAC ID: 0244565950 Enrollment ID: I20200114003758 |
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy.
The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.
For those who suffer from stomach ulcers, the daily routine of breakfast, lunch and dinner can be painful. A common cause of these ulcers, as well as other gastric malignancies, is a bacterium called Helicobacter pylori .
Guidant Corporation has received Conformité Européenne (CE) Mark approval to launch its CONTAK RENEWAL 4 cardiac resynchronization therapy defibrillators for use outside the United States.
Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.
› Verified 7 days ago
News Archive
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-080 for the treatment of Duchenne muscular dystrophy.
The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.
For those who suffer from stomach ulcers, the daily routine of breakfast, lunch and dinner can be painful. A common cause of these ulcers, as well as other gastric malignancies, is a bacterium called Helicobacter pylori .
Guidant Corporation has received Conformité Européenne (CE) Mark approval to launch its CONTAK RENEWAL 4 cardiac resynchronization therapy defibrillators for use outside the United States.
Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.
› Verified 7 days ago
Family Medicine Of Cullman Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1900 Main Ave Sw, Cullman, AL 35055 Phone: 256-642-9821 | |
North Alabama Medical Associates, P.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 117 2nd Ave Se, Cullman, AL 35055 Phone: 256-739-4144 Fax: 256-739-4595 | |
Cullman Regional Hospitalist Services, P.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1912 Al Highway 157, Cullman, AL 35058 Phone: 256-255-0228 Fax: 256-739-8350 | |
Cullman Primary Care, Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 408 Clark St Ne, Cullman, AL 35055 Phone: 256-734-3202 Fax: 256-734-4668 | |
Cullman Heart & Urgent Care Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1803 Park View Dr, Cullman, AL 35058 Phone: 256-255-1900 Fax: 256-255-1937 | |
Hawkins Medical And Wellness, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 421 3rd Ave Se Ste 145, Cullman, AL 35055 Phone: 318-422-3876 | |
Cullman Primary Care, Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1800 Al Highway 157 Ste 100, Cullman, AL 35058 Phone: 256-739-4131 Fax: 256-739-6027 |